Combination Chemotherapy and Cetuximab as First-Line Therapy in Treating Patients With Advanced and/or Metastatic Colorectal Cancer

NCT ID: NCT00640081

Last Updated: 2021-09-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 169 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2015-09-30

Brief Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving combination chemotherapy together with intermittent cetuximab is more effective than combination chemotherapy given together with continuous cetuximab in treating colorectal cancer.

PURPOSE: This randomized phase II trial is studying giving combination chemotherapy together with intermittent cetuximab to see how well it works compared to combination chemotherapy given together with continuous cetuximab as first-line therapy in treating patients with advanced or metastatic colorectal cancer.

Detailed Description

OBJECTIVES:

Primary

• To compare the activity, in terms of failure-free survival, of patients with K-ras-normal (wild type) advanced and/or metastatic colorectal cancer treated with intermittent combination chemotherapy comprising oxaliplatin, leucovorin calcium, and fluorouracil (OxMdG) or oxaliplatin and capecitabine (XELOX) and intermittent vs continuous cetuximab as first-line therapy.
• To compare the safety and feasibility of these regimens in these patients.

Secondary

• To compare the safety of cetuximab reintroduction, in terms of frequency of grade 3-4 allergic reactions in these patients.
• To compare improvement in disease control (i.e., complete response plus partial response plus stable disease) at 24 weeks in patients treated with these regimens.
• To compare overall and progression-free survival of patients treated with these regimens.
• To compare response rates at 12, 24, and 36 weeks in patients treated with these regimens.
• To compare toxicity of these regimens in these patients.

OUTLINE: This is a multicenter study. Patients are randomised to 1 of 2 treatment arms.

• Arm I (intermittent chemotherapy and intermittent cetuximab): Patients receive 1 of the following combination chemotherapy and cetuximab regimens:

• OxMdG: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Patients also receive cetuximab IV over 1-2 hours on days 1 and 8. Treatment repeats every 14 days for up to 6 courses (12 weeks) in the absence of disease progression or unacceptable toxicity.
• XELOX (for patients with line-related problems): Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine twice daily on days 1-15 (28 doses). Patients also receive cetuximab IV over 1-2 hours on days 1, 8, and 15. Treatment repeats every 21 days for up to 4 courses (12 weeks) in the absence of disease progression or unacceptable toxicity.

After completion of 12 weeks of study therapy, patients with disease progression are removed from study. Patients with stable or responding disease stop treatment with OxMdG or XELOX and cetuximab and undergo clinical evaluation at least every 6 weeks until disease progression or clinical deterioration. Upon evidence of disease progression or clinical deterioration, patients restart treatment with OxMdG or XELOX and cetuximab as before and continue to alternate 12 weeks of treatment with treatment breaks in the absence of disease progression or unacceptable toxicity. Patients with disease progression during study therapy stop treatment and proceed to second-line therapy or best supportive care.

• Arm II (intermittent chemotherapy and continuous cetuximab): Patients receive OxMdG or XELOX and cetuximab for 12 weeks as in arm I. Patients with disease progression after 12 weeks of study therapy are removed from study. Patients with stable or responding disease* after 12 weeks of study therapy stop treatment with OxMdG or XELOX and continue treatment with cetuximab weekly as monotherapy in the absence of disease progression or unacceptable toxicity. Patients undergo clinical evaluation as in arm I. Upon progression, patients restart treatment with OxMdG or XELOX and continue cetuximab, as before, alternating 12 weeks of combined OxMdG or XELOX and cetuximab therapy with cetuximab monotherapy. Patients with disease progression during study therapy stop treatment and proceed to second-line therapy as in arm I.

Previously collected tumor tissue samples are obtained at baseline and analyzed by IHC for EGFR status of tumor.

After completion of study treatment, patients are followed every 12 weeks.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.

Conditions

Colorectal Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

D

Intermittent chemotherapy plus intermittent cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period off all therapy, with reintroduction of the same chemotherapy and cetuximab regimen for a further 12 weeks after initial progression off treatment

Group Type: ACTIVE_COMPARATOR

cetuximab

Intervention Type: BIOLOGICAL

capecitabine

Intervention Type: DRUG

fluorouracil

Intervention Type: DRUG

leucovorin calcium

Intervention Type: DRUG

oxaliplatin

Intervention Type: DRUG

immunohistochemistry staining method

Intervention Type: OTHER

laboratory biomarker analysis

Intervention Type: OTHER

E

Intermittent chemotherapy plus continuous cetuximab treatment comprising 12 weeks of chemotherapy plus cetuximab followed by a period of withdrawal of the chemotherapy, but continued weekly cetuximab monotherapy (maintenance cetuximab), with reintroduction of the same chemotherapy regimen to the cetuximab for a further 12 weeks after initial progression off chemotherapy treatment

Group Type: EXPERIMENTAL

cetuximab

Intervention Type: BIOLOGICAL

capecitabine

Intervention Type: DRUG

fluorouracil

Intervention Type: DRUG

leucovorin calcium

Intervention Type: DRUG

oxaliplatin

Intervention Type: DRUG

immunohistochemistry staining method

Intervention Type: OTHER

laboratory biomarker analysis

Intervention Type: OTHER

Interventions

cetuximab

Intervention Type: BIOLOGICAL

capecitabine

Intervention Type: DRUG

fluorouracil

Intervention Type: DRUG

leucovorin calcium

Intervention Type: DRUG

oxaliplatin

Intervention Type: DRUG

immunohistochemistry staining method

Intervention Type: OTHER

laboratory biomarker analysis

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of colorectal adenocarcinoma, defined by 1 of the following:

• Prior or current histologically confirmed primary adenocarcinoma of colon or rectum with clinical or radiological evidence of advanced and/or metastatic disease
• Histologically and cytologically confirmed metastatic adenocarcinoma with clinical and/or radiological evidence of colorectal primary tumor
• Unidimensionally measurable disease by RECIST criteria
• Inoperable metastatic or locoregional disease

• Potentially resectable liver metastases allowed provided the following criteria are met:

• Fewer than 4 unilobar liver metastases, each < 4 cm in size and without major vascular involvement
• No combination chemotherapy allowed prior to the planned resection of operable liver metastases
• No confirmed K-ras mutation of tumor after screening
• No brain metastases

PATIENT CHARACTERISTICS:

• WHO performance status 0-2
• Must be considered fit to undergo combination chemotherapy
• ANC ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Serum bilirubin ≤ 1.25 times upper limit of normal (ULN)
• Alkaline phosphatase ≤ 5 times ULN
• AST or ALT ≤ 2.5 times ULN
• Creatinine clearance ≥ 50mL/min OR glomerular filtration rate ≥ 50 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No severe uncontrolled concurrent medical illness (including poorly controlled angina or myocardial infarction within the past 12 weeks) likely to interfere with protocol treatments
• No psychiatric or neurological condition that would preclude study compliance with oral medication or giving informed consent
• No partial or complete bowel obstruction
• No preexisting neuropathy > grade 1
• No prior or current malignant disease which, in the judgement of the treating investigator, is likely to interfere with COIN-B treatment or assessment of response
• No patients with known hypersensitivity reactions to any of the components of the study treatments
• No proven dihydropyrimidine dehydrogenase deficiency (DPD) or personal or family history of DPD

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior systemic palliative chemotherapy for metastatic disease
• No prior oxaliplatin
• More than 1 month since prior adjuvant chemotherapy comprising fluorouracil (with or without leucovorin calcium), capecitabine, or irinotecan hydrochloride
• More than 1 month since prior chemoradiotherapy comprising fluorouracil (with or without leucovorin calcium) or capecitabine for rectal cancer
• No ongoing requirement for contraindicated concurrent medication
• No concurrent enrollment in any type of study other than observational studies

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Cheryl Pugh

OTHER_GOV

Sponsor Role: lead

Responsible Party

Cheryl Pugh

Clinical Project manager for COINB for Sponsor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Harpreet S. Wasan

Role: PRINCIPAL_INVESTIGATOR

Hammersmith Hospitals NHS Trust

Locations

Bank of Cyprus Oncology Centre

Nicosia, , Cyprus

Bradford Royal Infirmary

Bradford, England, United Kingdom

Gloucestershire Oncology Centre at Cheltenham General Hospital

Cheltenham, England, United Kingdom

Essex County Hospital

Colchester, England, United Kingdom

Dorset County Hospital

Dorchester, England, United Kingdom

St. Luke's Cancer Centre at Royal Surrey County Hospital

Guildford, England, United Kingdom

Hammersmith Hospital

London, England, United Kingdom

St. Mary's Hospital

London, England, United Kingdom

Churchill Hospital

Oxford, England, United Kingdom

Peterborough Hospitals Trust

Peterborough, England, United Kingdom

University Hospital of North Staffordshire

Stoke-on-Trent, England, United Kingdom

Singleton Hospital

Swansea, Wales, United Kingdom

Royal United Hospital

Bath, , United Kingdom

Royal Bournemouth Hospital

Bournemouth, , United Kingdom

Addenbrookes Hospital

Cambridge, , United Kingdom

Darent Valley Hospital

Dartford, , United Kingdom

Hereford County Hospital

Hereford, , United Kingdom

Charing Cross Hospital

London, , United Kingdom

Guys and St Thomas' hospitals

London, , United Kingdom

Dorset Cancer Centre, Poole Hospital

Poole, , United Kingdom

Weston Park

Sheffield, , United Kingdom

Southport and Ormskirk

Southport, , United Kingdom

St Helens and Whiston hospitals

St Helens, , United Kingdom

Warrington and Halton Hospitals

Warrington, , United Kingdom

Worcestershire Royal Hospital

Worcester, , United Kingdom

Countries

Cyprus; United Kingdom

Study Documents

Document Type: Clinical Study Report

View Document

Related Links

http://www.ctu.mrc.ac.uk/our_research/research_areas/cancer/studies/coin_b/

Trial Summary on Sponsor's Website with trial citations

Other Identifiers

MRC-CTU-COIN-B/CR11

Identifier Type: -

Identifier Source: secondary_id

EUDRACT:2006-003049-17

Identifier Type: -

Identifier Source: secondary_id

ISRCTN38375681

Identifier Type: -

Identifier Source: secondary_id

EU-20828

Identifier Type: -

Identifier Source: secondary_id

MERCK-MRC-CTU-COIN-B/CR11

Identifier Type: -

Identifier Source: secondary_id

CDR0000589635

Identifier Type: -

Identifier Source: org_study_id